Lv6
2270 积分 2025-02-26 加入
Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study
1个月前
已完结
浅析人工智能/机器学习用于药品开发——基于FDA讨论文件的探讨
2个月前
已完结
Recent discoveries of Sino-Caucasian differences in the genetics of phaeochromocytomas and paragangliomas
3个月前
已关闭
[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study
4个月前
已完结
177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial
4个月前
已完结
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
4个月前
已完结
Belzutifan for Advanced Pheochromocytoma or Paraganglioma
6个月前
已完结
Belzutifan for Advanced Pheochromocytoma or Paraganglioma
6个月前
已完结
新型FAP靶向示踪剂64Cu-FAPI-XT117在恶性实体肿瘤中的初步临床研究：与18F-FDG的对比研究
7个月前
已完结
皖公网安备34019202002308
